Cargando…

Impact of veliparib, paclitaxel dosing regimen, and germline BRCA status on the primary treatment of serous ovarian cancer – an ancillary data analysis of the VELIA trial

OBJECTIVE. In the Phase 3 VELIA trial (NCT02470585), veliparib added to carboplatin plus paclitaxel concomitantly and as maintenance for women with newly-diagnosed advanced ovarian cancer significantly improved progression-free survival (PFS) versus chemotherapy alone. Here we present exploratory an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aghajanian, Carol, Swisher, Elizabeth M., Okamoto, Aikou, Steffensen, Karina Dahl, Bookman, Michael A., Fleming, Gini F., Friedlander, Michael, Moore, Kathleen N., Tewari, Krishnansu S., O’Malley, David M., Chan, John K., Ratajczak, Christine, Hashiba, Hideyuki, Wu, Meijing, Dinh, Minh H., Coleman, Robert L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9399938/ https://www.ncbi.nlm.nih.gov/pubmed/34930617 http://dx.doi.org/10.1016/j.ygyno.2021.12.012

Ejemplares similares

CA-125 KELIM as a Potential Complementary Tool for Predicting Veliparib Benefit: An Exploratory Analysis From the VELIA/GOG-3005 Study
por: You, Benoit, et al.
Publicado: (2023)

Veliparib with frontline chemotherapy and as maintenance in Japanese women with ovarian cancer: a subanalysis of efficacy, safety, and antiemetic use in the phase 3 VELIA trial
por: Mizuno, Mika, et al.
Publicado: (2022)

Velia and the school of Salerno.
por: Nutton, V
Publicado: (1971)

Volatiles of the Apicomplexan Alga Chromera velia and Associated Bacteria
por: Koteska, Diana, et al.
Publicado: (2022)

Relevance of Platinum-free Interval and BRCA Reversion Mutations for Veliparib Monotherapy after Progression on Carboplatin/Paclitaxel for gBRCA Advanced Breast Cancer (BROCADE3 Crossover)
por: Puhalla, Shannon L., et al.
Publicado: (2021)

Safety and efficacy of veliparib plus carboplatin/paclitaxel in patients with HER2-negative metastatic or locally advanced breast cancer: subgroup analyses by germline BRCA1/2 mutations and hormone receptor status from the phase-3 BROCADE3 trial
por: Ayoub, Jean-Pierre, et al.
Publicado: (2021)

Photosynthesis in Chromera velia Represents a Simple System with High Efficiency
por: Quigg, Antonietta, et al.
Publicado: (2012)

Using Diatom and Apicomplexan Models to Study the Heme Pathway of Chromera velia
por: Richtová, Jitka, et al.
Publicado: (2021)

The cell wall polysaccharides of a photosynthetic relative of apicomplexans, Chromera velia
por: Tortorelli, Giada, et al.
Publicado: (2021)

Subcellular Compartments Interplay for Carbon and Nitrogen Allocation in Chromera velia and Vitrella brassicaformis
por: Füssy, Zoltán, et al.
Publicado: (2019)

Transcriptomic Analysis Reveals the Roles of Detoxification Systems in Response to Mercury in Chromera velia
por: Sharaf, Abdoallah, et al.
Publicado: (2019)

Chromera velia, Endosymbioses and the Rhodoplex Hypothesis—Plastid Evolution in Cryptophytes, Alveolates, Stramenopiles, and Haptophytes (CASH Lineages)
por: Petersen, Jörn, et al.
Publicado: (2014)

Sustained Complete Response to Cytotoxic Therapy and the PARP Inhibitor Veliparib in Metastatic Castration-Resistant Prostate Cancer – A Case Report
por: VanderWeele, David J., et al.
Publicado: (2015)

Safety and pharmacokinetics of veliparib extended‐release in patients with advanced solid tumors: a phase I study
por: Werner, Theresa L., et al.
Publicado: (2018)

Phase 1 study of veliparib with carboplatin and weekly paclitaxel in Japanese patients with newly diagnosed ovarian cancer
por: Nishio, Shin, et al.
Publicado: (2017)

Phase 1 dose‐escalation study of single‐agent veliparib in Japanese patients with advanced solid tumors
por: Nishikawa, Tadaaki, et al.
Publicado: (2017)

Profile of veliparib and its potential in the treatment of solid tumors
por: Wagner, Lars M
Publicado: (2015)

Veliparib in combination with radiotherapy for the treatment of MGMT unmethylated glioblastoma
por: Jue, Toni Rose, et al.
Publicado: (2017)

Identification of Plant-like Galactolipids in Chromera velia, a Photosynthetic Relative of Malaria Parasites
por: Botté, Cyrille Y., et al.
Publicado: (2011)

Veliparib Is an Effective Radiosensitizing Agent in a Preclinical Model of Medulloblastoma
por: Buck, Jessica, et al.
Publicado: (2021)

Fifth annual workshop of cytoreductive surgery for advanced ovarian cancer and peritoneal surface malignancies
por: Tewari, Krishnansu S.
Publicado: (2016)

Therapeutic vaccination using HPV 16 E7 to eradicate CIN3
por: Tewari, Krishnansu S.
Publicado: (2019)

Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study
por: You, Benoit, et al.
Publicado: (2022)

Effect of the PARP inhibitor veliparib on germ cell tumor cell lines
por: Schmidtova, Silvia, et al.
Publicado: (2022)

Red and Problematic Green Phylogenetic Signals among Thousands of Nuclear Genes from the Photosynthetic Apicomplexan Chromera velia
por: Woehle, Christian, et al.
Publicado: (2012)

Phase II study of temozolomide and veliparib combination therapy for sorafenib-refractory advanced hepatocellular carcinoma
por: Gabrielson, Andrew, et al.
Publicado: (2015)

Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors
por: Bartelink, Imke H., et al.
Publicado: (2017)

Blocking PARP activity with the inhibitor veliparib enhances radiotherapy sensitivity in endometrial carcinoma
por: Wang, Jing, et al.
Publicado: (2022)

Synthesis of Veliparib Prodrugs and Determination of Drug-Release-Dependent PARP-1 Inhibition
por: Borgini, Matteo, et al.
Publicado: (2023)

Ancillary mathematics
por: Massey, Harrie Stewart Wilson, et al.
Publicado: (1959)

Red and Problematic Green Phylogenetic Signals among Thousands of Nuclear Genes from the Photosynthetic and Apicomplexa-Related Chromera velia
por: Woehle, Christian, et al.
Publicado: (2011)

A phase 1 study evaluating the pharmacokinetics and preliminary efficacy of veliparib (ABT-888) in combination with carboplatin/paclitaxel in Japanese subjects with non-small cell lung cancer (NSCLC)
por: Mizugaki, Hidenori, et al.
Publicado: (2015)

Emerging treatment options for management of malignant ascites in patients with ovarian cancer
por: Eskander, Ramez N, et al.
Publicado: (2012)

Beyond angiogenesis blockade: targeted therapy for advanced cervical cancer
por: Eskander, Ramez N., et al.
Publicado: (2014)

Epithelial cell-adhesion molecule-directed trifunctional antibody immunotherapy for symptom management of advanced ovarian cancer
por: Eskander, Ramez N, et al.
Publicado: (2013)

Toll-like receptor 8: augmentation of innate immunity in platinum resistant ovarian carcinoma
por: Brueseke, Taylor J, et al.
Publicado: (2013)

Targeted treatment of advanced ovarian cancer: spotlight on rucaparib
por: Pearre, Diana C, et al.
Publicado: (2018)

Anti-angiogenesis therapy, synthetic lethality, and checkpoint inhibition in ovarian cancer: state of the science and novel combinations
por: Liu, Marisa C, et al.
Publicado: (2018)

Highlights from the Gynecologic Oncology Track at the 2017 Annual Meeting of the American Society of Clinical Oncology
por: Wolford, Juliet E., et al.
Publicado: (2017)

Should adjuvant chemotherapy be formally studied among patients found to have pelvic lymph node metastases following radical hysterectomy with lymphadenectomy for early-stage cervical cancer?
por: Bujnak, Alyssa C., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_f3u6cnt7etmtcim5gosgemsoh1